A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.

Gurhan Kiziloz does not view his attention-deficit hyperactivity disorder (ADHD) as a liability. “It’s a superpower,” he said ...

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD). CTx-1301 is a ...

The number of people being diagnosed with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) ...

Empathy is essential, but when combined with guidance and structure, it enables children with disabilities to thrive ...

Access is especially tough for kids in rural areas or whose families don't have a lot of money. Some dentists say a new ...

ADHD is not rising despite public perception that cases are increasing, a study suggests. Researchers at King’s College ...

Trump's "MAHA" commission, led by RFK Jr., detailed four reasons they say causes childhood chronic disease. Here's what to ...

Prenatal exposure to triptans is not associated with increased risk for neurodevelopmental disorders in offspring, new ...

A global meta-analysis found that people with ADHD are significantly more likely to have irritable bowel syndrome (IBS), ...

Tris Pharma Inc. can’t be sued by the state of Texas for manipulating test results on medication to treat minors for ...